KLK3 and Familial prostate cancer: The study, prospectively conducted in three centers and based on 1244 patients who underwent biopsy, showed the value of PCA3 and TMPRSS2:ERG scores when they were added to the PCPT (Prostate Cancer Prevention Trial) risk calculator, also based on PSA and several clinical variables.